Simplifying Software Security: Veracode Enhances Frictionless Experience for Developers
14.9.2022 21:33:00 EEST | Business Wire | Press release
Black Hat (booth #2428) – Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform with substantial improvements to its integrated developer experience. New features include extended integrations to support software composition analysis (SCA), a software bill of materials (SBOM) Application Programming Interface (API), and additional language and framework support for static analysis, further enhancing developers’ ability to secure software in the environments where they work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005141/en/
Fig. 1 Veracode “Beat the Heat” security flaw heat map, State of Software Security Report v12 (Graphic: Business Wire)
Brian Roche, Chief Product Officer at Veracode, said, “Modern applications are mostly assembled, not written from scratch. Open-source code makes up a significant proportion of audited code bases—for example, 97 percent of the typical Java application is made up of open-source libraries*—increasing security risk and the need to identify supply chain risk. Our SBOM API, is designed to make it easier for developers to inventory their code base, including third-party components, allowing them to act quickly if new vulnerabilities emerge. Since the launch of our Continuous Software Security Platform in May, we have introduced additional capabilities that meet developers right where they work: in the integrated developer environment (IDE), code repository, and command line interface. These innovations are designed to drive adoption by making the platform even more developer friendly.”
Facilitating DevSecOps
Veracode’s platform supports 100+ languages and frameworks, including those for cloud-native application development and older languages used with legacy assets, like COBOL. Large enterprises have applications across myriad languages and being able to deploy a continuous security testing solution across them simplifies the process, while providing consistent results. The company’s latest State of Software Security (SoSS) 12 research analyzed the most common flaws by language and revealed that a prevalent flaw for one language may not be of any concern for another. For example, cross-site scripting (XSS) is the most common flaw for PHP, at 77 percent, but doesn’t even make the top 10 for C++*. Moreover, flaws change constantly, meaning that even if a flaw isn’t prevalent in a programming language, practitioners should still take active steps to prevent it from impacting their code. Since remediation tactics vary by flaw and programming language, having a broad array of language support in one place makes developers’ jobs easier by freeing up their time to focus on meeting tight deployment deadlines.
Frequent scanning of first- and third-party code mitigates the risk from both proprietary and open-source vulnerabilities, such as Log4j. Veracode’s new developer-centric tools and services are designed to make this a quicker and easier process, particularly with the additional capability of third-party proprietary library scanning.
Peter Evans, Engineering Director at QAD Precision GTTE, said, “Veracode brought a complete platform for us to build security tools into our development pipelines, as well as helped us grow our knowledge to keep getting better at security. Veracode was also a good fit because the platform can scan Java code in the Spring framework where we develop our software. We’ve gone from reviewing code to integrating continuous scans into our daily pipelines. Security threats don’t stand still and Veracode provides us the tools to keep up with the latest vulnerabilities and rules.”
Notable updates to the Veracode Continuous Software Security platform include:
SBOM for SCA
- With government regulations driving standards for securing software supply chains, having an SBOM is increasingly important for organizations. Veracode’s SBOM API in SCA enables developers to easily generate an SBOM in CycloneDX JSON format—one of the approved formats for compliance with the U.S. Executive Order. This helps confirm the code they’re using, or building, is free from vulnerabilities.
IDE and Integrations for SCA
To make software security a seamless experience, Veracode continues to introduce integrations that meet developers where they work.
- The Veracode Azure DevOps Extension has a new “SCA Flaw Importer” to automatically import SCA flaws into Azure DevOps Boards and Work Items
- The soon-to-be-released Veracode for Visual Studio Code extension provides detailed information on vulnerabilities, licence risks, and recommended versions of open-source libraries and transitive dependencies so developers can rapidly respond to any risks
Expanded Frameworks and Languages Support for Static Analysis
- The company is committed to keeping up with the latest language and frameworks with which developers work, adding support for Rails 7.0, Ruby 3.x, and PHP Symfony
Roche concluded, “As a pioneer of application security, we are uniquely positioned to combine unrivalled experience with the latest innovations in cloud development. Unlike on-premise vendors, our SaaS solution is both scalable and elastic, meaning customers are always prepared to meet unexpected demand. Powered by nearly two decades of cumulative data, our platform provides detailed comparative historical reviews against industry benchmarks and peers—a level of insight highly relevant for leadership teams and the board. Our platform also saves developers time by delivering highly accurate results and enabling them to find and fix vulnerabilities in minutes, meaning they can ship code quickly with the confidence that it is secure.”
Developers can learn more about Veracode’s platform, the frictionless developer experience, and how to simply and maturely secure their SDLC by visiting Veracode’s booth #2428 at Black Hat USA.
*Veracode State of Software Security Report v12, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005141/en/
Contact information
Press and Media
Katy Gwilliam
Head of Global PR, Veracode
kgwilliam@veracode.com
+44.7584.341.110
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom